Wedbush Reiterates Neutral on Alpine Immune Sciences, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated a Neutral rating on Alpine Immune Sciences (NASDAQ:ALPN) and maintained a $65 price target.
May 16, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst Robert Driscoll has reiterated a Neutral rating on Alpine Immune Sciences (NASDAQ:ALPN) and maintained a $65 price target.
The reiteration of a Neutral rating and maintenance of the $65 price target by Wedbush suggests that there are no significant changes in the analyst's outlook for Alpine Immune Sciences. This is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100